This morning, Helus Pharma announced the appointment of Michael Cola as CEO. Here, Psychedelic Alpha’s Josh Hardman speaks with the newly appointed executive in a brief Q&A on execution, regulatory rigour, and scaling serotonergic CNS medicines.
Josh Hardman, Psychedelic Alpha: How does your background in specialty pharma support Helus?
Michael Cola, Helus: I have spent my career taking differentiated medicines from late-stage development through approval and into real-world use, which is often where CNS programs struggle most
To read this interview, please sign in to your Pα+ account…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
